Actively Recruiting
Open-Label Phase 2 Study Evaluating Povorcitinib Safety and Pharmacokinetics in Adolescents with Moderate to Severe Hidradenitis Suppurativa
Led by Incyte Corporation · Updated on 2026-10-09
40
Participants Needed
30
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating povorcitinib, an oral tablet, for its pharmacokinetics, safety, and efficacy in adolescents aged 12 to 17 years with moderate to severe hidradenitis suppurativa HS. The study focuses on this condition, characterized by painful skin lesions, and aims to understand how the drug behaves in the body and its impact on disease symptoms over a 54-week treatment period. Participants will receive one of two doses of povorcitinib for 54 weeks in an open-label, non-randomized design. The study includes regular monitoring of drug levels in the blood up to Week 24. The two dose groups will help evaluate differences in treatment effects and safety over the full treatment duration. During the trial, participants will be assessed for adverse events, drug clearance, absorption, and concentration levels. The study will also measure clinical responses such as reduction in abscesses, inflammatory nodules, draining tunnels, skin pain, and quality of life changes using specific scales over 54 weeks. Safety and efficacy data will be collected throughout, with a primary focus on treatment-emergent adverse events and drug pharmacokinetics.
CONDITIONS
Brief Title
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Research Team
I
Incyte Corporation Call Center (US)
I
Incyte Corporation Call Center (ex-US)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here